Zacks Investment Research cut shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a buy rating to a hold rating in a research note issued to investors on Tuesday.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

PRQR has been the topic of several other research reports. ValuEngine upgraded shares of ProQR Therapeutics N.V. from a strong sell rating to a sell rating in a research note on Friday, September 1st. HC Wainwright restated a buy rating and issued a $40.00 target price on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $14.30.

ProQR Therapeutics N.V. (PRQR) remained flat at $5.95 during trading on Tuesday. 37,913 shares of the stock were exchanged. The firm’s market capitalization is $143.42 million. ProQR Therapeutics N.V. has a 52 week low of $3.65 and a 52 week high of $8.70. The stock’s 50 day moving average is $5.08 and its 200 day moving average is $4.95.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/09/15/zacks-investment-research-lowers-proqr-therapeutics-n-v-prqr-to-hold.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sphera Funds Management LTD. lifted its position in ProQR Therapeutics N.V. by 65.0% during the 1st quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock worth $1,650,000 after buying an additional 130,000 shares in the last quarter. Janus Henderson Group PLC acquired a new position in ProQR Therapeutics N.V. during the 2nd quarter worth about $2,028,000. Artal Group S.A. lifted its position in ProQR Therapeutics N.V. by 25.0% during the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after buying an additional 100,000 shares in the last quarter. Finally, Redmile Group LLC lifted its position in ProQR Therapeutics N.V. by 2.8% during the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after buying an additional 43,050 shares in the last quarter. Institutional investors and hedge funds own 35.93% of the company’s stock.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get a free copy of the Zacks research report on ProQR Therapeutics N.V. (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.